ARMATA PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $2.37M.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $0.00.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2022-06-30 was -$32.00K.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2022 was $44.39M, a 68.75% increase from fiscal 2021.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2021 was $26.31M, a 15.33% increase from fiscal 2020.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2020 was $22.81M, a 128.67% increase from fiscal 2019.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2019 was $9.97M, a 61.98% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $2.37M 10-Q · filed 2026-08-12 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $44.39M 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $51.33M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $51.33M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $44.42M 10-Q · filed 2023-05-11 | $51.37M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $6.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $26.31M 10-K · filed 2023-03-16 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $19.36M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $19.36M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $19.36M 10-Q · filed 2022-05-12 | $19.33M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $22.81M 10-K · filed 2022-03-17 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $22.81M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $22.81M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $22.84M 10-Q · filed 2021-05-13 | $32.82M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $9.97M 10-K · filed 2021-03-18 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | |
| 2019-06-30 | $9.97M 10-Q · filed 2020-08-13 | |
| 2018-12-31 | $6.16M 10-K · filed 2019-03-25 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-27 | $8.27M 10-K · filed 2017-03-27 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | |
| 2015-03-31 | $8.27M 10-Q · filed 2015-05-15 | |
| 2013-12-31 | $3.00M 10-Q/A · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |